1. Home
  2. URGN vs LEG Comparison

URGN vs LEG Comparison

Compare URGN & LEG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

HOLD

Current Price

$21.96

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Logo Leggett & Platt Incorporated

LEG

Leggett & Platt Incorporated

HOLD

Current Price

$11.67

Market Cap

1.2B

ML Signal

HOLD

Company Overview

Basic Information
Metric
URGN
LEG
Founded
2004
1883
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Home Furnishings
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.2B
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
URGN
LEG
Price
$21.96
$11.67
Analyst Decision
Strong Buy
Hold
Analyst Count
8
4
Target Price
$28.50
$10.50
AVG Volume (30 Days)
998.4K
2.4M
Earning Date
11-06-2025
10-27-2025
Dividend Yield
N/A
1.73%
EPS Growth
N/A
N/A
EPS
N/A
1.61
Revenue
$96,516,000.00
$4,172,899,999.00
Revenue This Year
$27.96
N/A
Revenue Next Year
$123.02
N/A
P/E Ratio
N/A
$7.19
Revenue Growth
8.00
N/A
52 Week Low
$3.42
$6.48
52 Week High
$30.00
$12.03

Technical Indicators

Market Signals
Indicator
URGN
LEG
Relative Strength Index (RSI) 42.19 70.95
Support Level $21.74 $10.86
Resistance Level $30.00 $11.54
Average True Range (ATR) 1.56 0.41
MACD -0.72 0.09
Stochastic Oscillator 3.15 88.45

Price Performance

Historical Comparison
URGN
LEG

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

About LEG Leggett & Platt Incorporated

Leggett & Platt Inc designs and produces engineered components and products found in homes and automobiles. It operates its business through three segments namely Bedding Products, Specialized Products, and Furniture, Flooring, and Textile Products. It generates the majority of its revenue from Bedding Products. Serving a broad suite of customers around the world, Leggett & Platt's products include bedding components, automotive seat support, and lumbar systems, specialty bedding foam and private label finished mattresses, components for home furniture, and work furniture, flooring underlayment, adjustable beds, and various other products.

Share on Social Networks: